198 related articles for article (PubMed ID: 26666929)
1. Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival.
Rhodes NJ; Kuti JL; Nicolau DP; Van Wart S; Nicasio AM; Liu J; Lee BJ; Neely MN; Scheetz MH
Antimicrob Agents Chemother; 2015 Dec; 60(3):1401-10. PubMed ID: 26666929
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of clinical outcomes in patients with Gram-negative bloodstream infections according to cefepime MIC.
Rhodes NJ; Liu J; McLaughlin MM; Qi C; Scheetz MH
Diagn Microbiol Infect Dis; 2015 Jun; 82(2):165-71. PubMed ID: 25801780
[TBL] [Abstract][Full Text] [Related]
3. Effect of cefepime dose on mortality of patients with Gram-negative bacterial bloodstream infections: a prospective cohort study.
Alves MD; Ribeiro VB; Tessari JP; Mattiello F; De Bacco G; Luz DI; Vieira FJ; Behle TF; Pasqualotto AC; Zavascki AP
J Antimicrob Chemother; 2014 Jun; 69(6):1681-7. PubMed ID: 24474430
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa.
Crandon JL; Bulik CC; Kuti JL; Nicolau DP
Antimicrob Agents Chemother; 2010 Mar; 54(3):1111-6. PubMed ID: 20038614
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
[TBL] [Abstract][Full Text] [Related]
6. Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia.
Aitken SL; Altshuler J; Guervil DJ; Hirsch EB; Ostrosky-Zeichner LL; Ericsson CD; Tam VH
Int J Antimicrob Agents; 2015 May; 45(5):541-4. PubMed ID: 25665726
[TBL] [Abstract][Full Text] [Related]
7. Defining the impact of severity of illness on time above the MIC threshold for cefepime in Gram-negative bacteraemia: a 'Goldilocks' window.
Miglis C; Rhodes NJ; Kuti JL; Nicolau DP; Van Wart SA; Scheetz MH
Int J Antimicrob Agents; 2017 Sep; 50(3):487-490. PubMed ID: 28668683
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of clinical outcomes in patients with bloodstream infections due to Gram-negative bacteria according to carbapenem MIC stratification.
Esterly JS; Wagner J; McLaughlin MM; Postelnick MJ; Qi C; Scheetz MH
Antimicrob Agents Chemother; 2012 Sep; 56(9):4885-90. PubMed ID: 22777044
[TBL] [Abstract][Full Text] [Related]
9. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients.
Cheatham SC; Shea KM; Healy DP; Humphrey ML; Fleming MR; Wack MF; Smith DW; Sowinski KM; Kays MB
Int J Antimicrob Agents; 2011 Jan; 37(1):46-50. PubMed ID: 21074370
[TBL] [Abstract][Full Text] [Related]
10. Cefepime dosing in the morbidly obese patient population.
Rich BS; Keel R; Ho VP; Turbendian H; Afaneh CI; Dakin GF; Pomp A; Nicolau DP; Barie PS
Obes Surg; 2012 Mar; 22(3):465-71. PubMed ID: 22249886
[TBL] [Abstract][Full Text] [Related]
11. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
Deal EN; Micek ST; Reichley RM; Ritchie DJ
Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
[TBL] [Abstract][Full Text] [Related]
12. Quantifying the importance of active antimicrobial therapy among patients with Gram-negative bloodstream infections: Cefepime as a representative agent.
Miglis C; Rhodes NJ; Liu J; Gener J; Hang E; Scheetz MH
Int J Antimicrob Agents; 2019 Jan; 53(1):95-97. PubMed ID: 30315921
[TBL] [Abstract][Full Text] [Related]
13. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
Burgess DS; Frei CR
J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
[TBL] [Abstract][Full Text] [Related]
14. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.
Lodise TP; Pypstra R; Kahn JB; Murthy BP; Kimko HC; Bush K; Noel GJ; Drusano GL
Antimicrob Agents Chemother; 2007 Jul; 51(7):2378-87. PubMed ID: 17387149
[TBL] [Abstract][Full Text] [Related]
15. Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study.
Arnold HM; Hollands JM; Skrupky LP; Smith JR; Juang PH; Hampton NB; McCormick S; Reichley RM; Hoban A; Hoffmann J; Micek ST; Kollef MH
Ann Pharmacother; 2013 Feb; 47(2):170-80. PubMed ID: 23341160
[TBL] [Abstract][Full Text] [Related]
16. Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen.
Georges B; Conil JM; Cougot P; Decun JF; Archambaud M; Seguin T; Chabanon G; Virenque C; Houin G; Saivin S
Int J Clin Pharmacol Ther; 2005 Aug; 43(8):360-9. PubMed ID: 16119511
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia.
MacVane SH; Kuti JL; Nicolau DP
Antimicrob Agents Chemother; 2014; 58(3):1359-64. PubMed ID: 24342637
[TBL] [Abstract][Full Text] [Related]
18. Cefepime pharmacodynamics in patients with extended spectrum beta-lactamase (ESBL) and non-ESBL infections.
Lee SY; Kuti JL; Nicolau DP
J Infect; 2007 May; 54(5):463-8. PubMed ID: 17067681
[TBL] [Abstract][Full Text] [Related]
19. Effect of differences in MIC values on clinical outcomes in patients with bloodstream infections caused by gram-negative organisms treated with levofloxacin.
Defife R; Scheetz MH; Feinglass JM; Postelnick MJ; Scarsi KK
Antimicrob Agents Chemother; 2009 Mar; 53(3):1074-9. PubMed ID: 19075047
[TBL] [Abstract][Full Text] [Related]
20. Impact of body mass index on clinical outcomes in patients with gram-negative bacteria bloodstream infections.
Lizza BD; Rhodes NJ; Esterly JS; Toy C; Lopez J; Scheetz MH
J Infect Chemother; 2016 Oct; 22(10):671-6. PubMed ID: 27590417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
